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Recent interest in cardiac arrhythmias in chil-
dren has been motivated by a growing aware-
ness and understanding of primai}^ rhythm dis-
orders in the young as well as by an increasing
emergence of cardiac arrhythmias following
surgical repair of many congenital heart de-
fects.̂  An increased understanding and use of
both conventional and investigational antiar-
rhythmic medications in children has, by neces-
sity, accompanied this clinical development. Of
particular interest is the emergence of amio-
darone hydrochloride, an iodinated benzofuran
derivative, in the treatment of arrhythmias. This
article focuses on the electophysiology, pharma-
cology, experience, side effects, dosages, and
indications for amiodarone especially relevant
to the pediatric patient.
Electrophysiology and Pharmocology
The electrophysiological effects and pharma-
cology of amiodarone are reviewed elsewhere
in this issue. Among the observed electrophys-
iological changes induced by amiodarone are
a slowing of the spontaneous sinus node dis-
charge rate, slowing of atrioventricular conduc-
tion, and prolongation of atrial and ventricular
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effective refractory periods.- Both acute intra-
venous and chronic oral amiodarone prolong
adult human and canine ventricular repolariza-
tion (type III effects)^ and exhibit rate-related
prolongation of the ventricular action potential
as well as QRS duration (type I effects)"* Re-
cent work by Yabek and associates suggests
important age-dependent effects of amio-
darone.^ Acute data from the neonatal canine
ventricle have demonstrated no change in ven-
tricular repolarization, suggesting a decreased
sensitivity to amiodarone in the young mam-
malian myocardium. Further, amiodarone pro-
duces a greater concentration-dependent short-
ening of the action potential and effective re-
fractory period of neonatal canine Purkinje
fibers when compared to the effects on the adult
canine Purkinje fiber. In contrast, rate-related
decreases in the action potential amplitude and
^max ^^ both neonatal and adult tissues are
similar, and thus are not age-dependent. These
findings suggest that, when compared to the
adult myocardium, type III effects may be less
operative in the immature myocardium in
which dispersion of refractoriness is minimal.
Furthermore, the rate-related type I antiar-
rhythmic action of amiodarone may be of par-
ticular significance in the young in whom both
the baseline and tachycardia heart rate tend to
be higher.-̂
The pharmacokinetics of orally administered
amiodarone are significantly different between
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the adult and child. The time of onset of thera-
peutic effect is four to five days in the pediatric
population compared to nine to ten days in the
adult population.^^ Although the elimination
of the drug by both groups is biexponential with
an initial rapid phase followed by a more pro-
longed second phase due to clearance from tis-
sue stores, the half-life of this elimination is two
to three weeks in children compared to two to
four months in the adult, perhaps due to a
more rapid equilibration of the drug between
plasma and tissue in the young.^^ In both
children and adults, amiodarone is metabolized
in part by the liver to the nonactive desethylam-
iodarone; this metabolite and the parent drug
are then cleared by the liver. Therapeutic
plasma concentrations, considered to be be-
tween 1.0 and 2.5 /̂ g/ml, correlate only fairly
with either beneficial effect or side effects.̂ -̂ "
On the other hand, correlation has been shown
between therapeutic antiarrhythmic effect and
prolongation of the QT interval in adults receiv-
ing 400-600 mg of amiodarone per day."
Information regarding the fetal pharmacology
of amiodarone is incomplete. A 27-week gesta-
tion fetus with atrial flutter (260 bpm) was
treated by oral administration of amiodarone
(in conjunction with verapamil) to the mother.
The fetal ventricular rate slowed with resolution
of fetal heart failure. The fetus progressed to
term without adverse outcome; direct current
cardioverison to sinus rhythm was achieved at
24 hours of age.^ In two other women who
were undergoing treatment for arrhythmia in
the third trimester, the fetal-to-maternal plasma
concentration ratio was 0.2 and 0.25 without
adverse side effects.̂  In another report, the
mother was treated with amiodarone (200 mg
per day maintenance dose) for supraventricular
tachycardia beginning at the 16th week. Deliv-
ery at 39 weeks of a normal newborn was un-
eventful. Nine hours after the last maternal
dose, the cord blood amiodarone concentration
was 0.08 ^g/ml, the placenta serum concentra-
tion, 0.23 /ig/ml, and the placental tissue con-
centration, 7.2 Mg/g '̂ similar to reported heart
tissue concentrations after chronic therapy.^
The mother's amiodarone serum level was
0.8 /ig/ml. Maternal and infant thyroid studies
were normal. At two weeks of age the child's
amiodarone serum was 0.06 figlrrd. The infant's
QTc was 0.49 seconds at 24 hours of age, and
0.39 seconds at 7 weeks of age.^ Thus the
fetal-to-matemal serum concentration ratio in
this infant at delivery was approximately 0.1,
demonstrating transplacental passage but no
adverse fetal effects aiter continuous exposure
to amiodarone beginning early in the sec-
ond trimester. This small experience suggests
that amiodarone may be safe in the second and
third trimester. On the other hand, since there
are no reports of first-trimester use, and because
of the widespread tissue distribution as well as
the multiple organ toxicity in the adult, the pos-
sibility of teratogenesis during the first trimes-
ter may be great; thus, we suggest that the drug
should not be used in early pregnancy, and
perhaps only sparingly in later pregnancy.
Clinical Experience
Amiodarone has been remarkably effective in
reducing the rate and frequency of either auto-
matic or reentrant supraventricular and ventric-
ular arrhythmias in children. We were able to
find detailed documentation of approximately
200 children reported in the literature (Table I),
the vast majority reported by Coumel." Amio-
darone was effective in controlling most atrial
arrhythmias. Because of its effect of prolonging
the refractory period of the accessory pathway
connection as well as decreasing the conduction
velocity of the circus movement in different
parts of the circuit, ̂ "̂  amiodarone is especially
useful for control of arrhythmias in patients
with the Wolff-Parkinson-White syndrome,^
including children. '̂̂  Coumel^ reports fair to
good (normal sinus rhythm or a marked de-
crease in frequency and rate of the tachycardia)
in 92% (86 of 93) of children with atrial arrhyth-
mias and 85% of children with ventricular ar-
rhythmias. Garson^ reported complete or par-
tial effectiveness of amiodarone in 96% of chil-
dren with atrial flutter, 86% of children with
ventricular tachcardia, and 78% of patients with
supraventricular tachycardia (overall success
87%). Among our 7 patients who have received
amiodarone (3 with supraventricular tachy-























































































































































*The majority were patients with supraventricular tachycardia, not otherwise specified.
"Where applicable, the first number indicates patients with successlul response and Ihe second indicates the
total number of patients.
cardia, 2 with atrial fibrillation, 1 with atrial flut-
ter, and 1 with syncope and ventricular fibrilla-
tion), all but the 2 patients with atrial fibrillation
were improved.
In contrast to prior experience in which junc-
tional ectopic tachcardia was notoriously diffi-
cult to treat with any medication and was asso-
ciated with a significant mortality, ̂ ^ a bene-
ficial response was noted in most patients with
functional arrhythmias. One patient died sud-
denly with junctional ectopic tachycardia after
experiencing initial clinical improvement/
Several authors have reported success in con-
trolling ventricular tachycardia/ventricular fibril-
lation in 52-69% of adult patients at 12-14
months,i*̂ --*̂ * and 29% at 24 months.-'^ Experi-
ence with ventricular tachycardia in children,
due to the different distribution of arrhythmias
between adults and children along with the vir-
tual absence of clinical ischemic heart disease
in children, is less extensive; accumulated data
(Table I) indicate approximately 87% favorable
response to amiodarone in children with ven-
tricular arrhythmias.^'"^
This overall experience is even more impres-
sive in view of the fact that the drug was avail-
able only as an investigational agent in the
United States until March 1986 and that many
of these arrhythmias had failed control with
more conventional agents. Thus, selection of
these patients, at least in the North American
experience, is weighted toward children with
intractable, difficult-to-manage arrhythmias.
Side Effects
The type and frequency of side effects in
children are at variance with the adult exper-
ience. The latter experience indicates that cor-
neal, cutaneous, gastrointestinal, hepatic, neur-
ological, endocrine, renal, pulmonary, and
proarrhythmic side effects are not uncom-
jT̂ Qĵ  lo.L̂  These side effects have been reported
in approximately 50% of patients.^ '̂̂ -^ '̂̂  Pul-
monary fibrosis, occurring in 1-6% of
adults,'̂ •-'̂ •" and proarrhythmic effects are the
most serious in adults. Neurological complaints
including tremors and peripheral neuropathy
are frequent in adults, occurring in 50%.^
In contrast to the adult population, most re-
ports (Table II) have cited few significant side
effects in children. Neurological symptoms in
children may present as alterations in behavior
(nightmares or personality changes).•• Pul-
monary fibrosis is unreported in the young;
fatal hepatic failure has been reported.'̂ '* We
have seen proarrhythmic effects (increased ven-
tricular ectopic activity) in a 16-year-old girl. The
patient was successfully managed with both
amiodarone and procainamide initially. Pro-
cainamide was then gradually withdrawn, uith
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successful suppression of both her supraven-
tricular and ventrictilar arrhythrruas with amio-
darone alone. Children with side effects tend
to be older (> 10 years of age)"̂ '' as well as to
receive a higher dose {>400 mg per day). In
only 12 of 215 children (9%) was amiodarone
withdrawn specifically because of adverse ef-
fects. A reverse T3 level > 90 ng/dL has been
associated with significant side effects in
children/
The one major exception with regard to side
effects in the child may be hypothyroidism,
exemplified by the report of Costigan and asso-
ciates.-^ These investigators prospectively
studied 15 children receiving amiodarone.
Three infants {11-41 months) developed either
clinical or biochemical hypothyroidism; two
required treatment. These three children, be-
cause of the severity of the arrhythymia, re-
quired the highest dosage per kilogram per day
to control their arrhythmia. This incidence {3
of 15) is higher than appreciated in previous
reports in children, and underscores, by the
clustering in the 3-41-month-old child, the im-
portance of monitoring thyroid function, in-
cluding reverse T3, in the young receiving
amiodarone. Although more of a direct and
predictable effect on atrioventricular conduction
than a side effect, 5 of the 214 patients required
pacemaker implantation because of de-
terioration in atrioventricular conduction.̂ '̂ -̂ ^
An adverse interaction with other drugs may
occur. Digoxin levels are increased while a child
is taking amiodarone due to reduced renal
clearance of digoxin resulting from decreased
digoxin secretion as well as an amiodarone-
induced decrease in the volume of distribution.
The child should have his digoxin dose reduced
by one-half if he or she receives amiodarone
concomitantly. Further, there is a high risk of
toxic interaction with many type I antiarrhyth-
mia agents; bradycardia and hypotension have
been reported with concomitant use of beta
blocking and calcium channel blocking
agents.-'' Finally, amiodarone has been shown
to potentiate the effects of warfarin.^-^ In gen-
eral, side effects appear to be less frequent and
less severe in the young; nonetheless, because
of the unknown long-term effects of amio-
darone in the growing child, the development
of possible side effects must be carefully
monitored.
Dosage
The dosage of amiodarone varies widely;
loading doses will vary from 10-60 mg/kg/day
for 3-5 days with maintenance doses varying
from 5-27 mg/kg/day. In general, most patients
are loaded with the lower dose range and can
then be maintained on 5-10 mg/kg/day.'-^''
Supraventricular tachycardia generally requires
a lower dose for successful response than does
ventricular tachycardia. Because serious side
effects are dose-related, efforts to reduce the
dose to minimal levels that control the arrhyth-
mia are desirable. Therapeutic and toxic re-
sponses can be monitored by measuring serum
reverse T3 concentrations/-'' Although some
children have received amiodarone for as long
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as six years,*" more long-term (more than one
year) experience in children is limited.
Indications and Conclusion
Amiodarone has many of the attributes of the
ideal universal antiarrhythmic agent. It has a
long half-life, can be administered once a day,
and often less frequently, is highly effective,
especially in supraventricular tachycardia, and
appears to be well tolerated in children. None-
theless, the toxicit}^ although considerably less
in terms of lethal dose by weight compared to
other antiarrhythmic agents, involves virtually
every organ system. Its effects on the growing
child are unknown and should be considered
potentially very serious. Thus, amiodarone
should be reserved for the child with life-threat-
ening and/or cardiac disabling arrhythmias only
after other forms of treatment have been ex-
hausted. Although the drug has been released
in the United States by the FDA, its use is con-
fined to adults with life-threatening ventricular
arrhythmias. Thus, its use in children should
be reserved for clearly life-threatening or intract-
able disabling arrhythmias until further data re-
garding its effect on human development are
available.
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